123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma: Reply

Journal of Nuclear Medicine

Volumn 51, Issue 2, 2010, Pages 331-

  Sharp, Susan E ^a   Shulkin, Barry L ^b   Gelfand, Michael J ^b   Salisbury, Shelia ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; FLUORODEOXYGLUCOSE F 18;

CANCER DIAGNOSIS; CONFIDENCE INTERVAL; DIAGNOSTIC IMAGING; DISEASE COURSE; FOLLOW UP; HUMAN; LETTER; NEUROBLASTOMA; PRIORITY JOURNAL; SAMPLE SIZE; SAMPLING ERROR;

EID: 75749107068     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.070003     Document Type: Letter

References (2)

1. 18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50:1237-1243.
2. Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol. 2001;19:3397-3405.